These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening.
    Author: Li L, Guo Z, Wang J, Mao Y, Gao Q.
    Journal: Dig Dis Sci; 2012 Nov; 57(11):2910-6. PubMed ID: 22865399.
    Abstract:
    BACKGROUND: Alpha-fetoprotein detection is currently mainly used in clinic for diagnosis of primary hepatocellular carcinoma (HCC). However, its sensitivity and specificity are not satisfying. Approximately 60-80 % of patients with HCC have an established background of chronic infection with hepatitis B virus (HBV). AIMS: To investigate the potential of serum microRNAs (miRNAs) as biomarkers for HBV-related HCC. METHODS: This study was divided into two phases: firstly, marker (miR-95, miR-18a, miR-10b, miR125a, and miR-378) detection by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) in sera from HBV patients with HCC (n = 15) and health subject (n = 15); and, secondly, marker validation by real-time qRT-PCR on HBV patients with HCC (n = 86) or hepatitis or cirrhosis (n = 30), and healthy subject (n = 45). RESULTS: Serum miR-18a was significantly higher in HBV patients with HCC than healthy controls (p < 0.01); serum miR-378 was significantly lower in HBV patients with HCC compared to healthy control (p < 0.05). Receiver operating characteristic (ROC) curve analyses suggested that serum miR-18a had significant diagnostic value for HBV-related HCC. MiR-18a yielded an area under the curve (AUC) of ROC of 0.881 with 86.1 % sensitivity and 75.0 % specificity in discriminating HBV-related HCC from healthy controls, and an AUC of ROC of 0.775 with 77.2 % sensitivity and 70.0 % specificity in discriminating HBV-related HCC from chronic hepatitis or cirrhosis. CONCLUSIONS: Our results suggest that serum miR-18a might serve as a novel and potential noninvasive biomarker for HBV-related HCC screening.
    [Abstract] [Full Text] [Related] [New Search]